Absci (ABSI) vs bioAffinity Technologies (BIAF)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Absci is the larger company by market cap ($1.75 billion vs $5.7 million), about 307.9 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABSI | BIAF |
|---|---|---|
| Share price | $10.20 | $4.87 |
| Market cap | $1.75B | $5.68M |
| 1-day change | +14.04% | -13.65% |
| YTD return | +156.16% | — |
| 1-year return | +113.88% | — |
| 5-year return | -15.90% | — |
| EPS (TTM) | $-0.79 | $-109.35 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $2.80M | — |
| Revenue growth (YoY) | -38.24% | — |
| Net income (latest FY) | $-115.18M | — |
| Operating margin | -4297.04% | — |
| Net margin | -4113.68% | — |
| 52-week high | $12.06 | $80.70 |
| 52-week low | $2.24 | $4.56 |
| Distance from 52-week high | -15.43% | -93.97% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +41.25% | — |
| Average volume | 3.45M | 3.67M |
| Shares outstanding | 171.61M | 1.17M |
| Employees | 140 | 57 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Biotechnology: Commercial Physical & Biological Resarch |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Absci is about 307.9 times larger than bioAffinity Technologies by market value ($1.75B vs $5.68M).
About Absci
ABSI stock →Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology.
Health Care · Biotechnology: Commercial Physical & Biological Resarch · 140 employees
About bioAffinity Technologies
BIAF stock →bioAffinity Technologies, Inc. engages in developing non-invasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States.
Health Care · Biotechnology: Commercial Physical & Biological Resarch · 57 employees
ABSI vs BIAF FAQ
Which is bigger, Absci or bioAffinity Technologies?
Absci (ABSI) is larger, with a market capitalization of $1.75B compared with $5.68M for bioAffinity Technologies (BIAF).
Are Absci and bioAffinity Technologies in the same industry?
Yes. Both are classified in the Biotechnology: Commercial Physical & Biological Resarch industry within the Health Care sector.